CHST10 Antibody

What is CHST10 and why is it relevant to neuroscience research?

CHST10, also known as HNK-1 sulfotransferase (HNK-1ST), belongs to the sulfotransferase 2 family and catalyzes the transfer of sulfate groups to carbohydrates. This enzyme has a calculated molecular weight of approximately 42 kDa, although it is often detected at 72 kDa in Western blot applications due to post-translational modifications . CHST10 is particularly relevant to neuroscience research due to its role in the biosynthesis of the HNK-1 epitope, which is expressed on several neural cell adhesion molecules and is involved in cell migration, synaptic plasticity, and memory formation. Its expression in neural tissues makes it a target of interest in studies of neurodevelopmental and neurodegenerative conditions.

What are the primary research applications for CHST10 antibodies?

CHST10 antibodies have diverse applications in neuroscience and cell biology research. The most common applications include Western blotting (WB) for protein expression analysis, immunohistochemistry (IHC) for tissue localization studies, immunocytochemistry (ICC) for cellular localization, immunofluorescence (IF) for high-resolution imaging, and enzyme-linked immunosorbent assay (ELISA) for quantitative analysis . These applications enable researchers to investigate CHST10's expression patterns, subcellular localization, and potential involvement in various neurological conditions. The selection of the appropriate application depends on the specific research question being addressed.

Which experimental models are most suitable for CHST10 research?

CHST10 antibodies have been validated for research with human, mouse, and rat samples, making these species appropriate models for investigating CHST10 function . Cell lines derived from these species can be used for in vitro studies, while tissue samples are suitable for ex vivo analyses. For developmental studies, mouse and rat models are particularly valuable due to the well-characterized developmental timeline and the availability of genetic manipulation tools. When selecting an experimental model, researchers should consider the specific CHST10 antibody's validated reactivity spectrum to ensure appropriate cross-reactivity with the target species.

How can I validate the specificity of a CHST10 antibody?

Validating CHST10 antibody specificity requires a multi-pronged approach. The gold standard validation method employs genetic controls, particularly knockout (KO) cell lines, where antibody reactivity should be absent in CHST10-knockout samples but present in parental/wild-type lines . Other complementary validation strategies include:

• Western blot analysis with positive and negative control lysates

• Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide

• siRNA knockdown of CHST10 in relevant cell types

• Cross-validation with multiple antibodies targeting different epitopes of CHST10

Research indicates that validation using genetic approaches (particularly KO controls) is significantly more reliable than orthogonal approaches, with antibodies validated by genetic strategies showing 80-89% confirmation rates compared to lower rates for orthogonal methods .

What are the advantages of using knockout cell lines for CHST10 antibody validation?

Knockout (KO) cell lines represent the most rigorous approach to CHST10 antibody validation. This method offers several distinct advantages:

• Provides unambiguous confirmation of antibody specificity by eliminating the target protein

• Enables clear identification of non-specific binding to other proteins

• Reduces the risk of false positive results in all applications (WB, IF, IHC, IP)

• Reveals potential cross-reactivity issues that other validation methods might miss

Studies have demonstrated that genetic validation approaches using KO cells result in significantly higher confirmed antibody performance (80-89%) compared to orthogonal approaches, especially for immunofluorescence applications where only 38% of antibodies validated by orthogonal methods were confirmed using KO controls . While generating custom KO cell lines can be costly, their value in ensuring experimental reproducibility justifies the investment for critical research applications.

Why might there be discrepancies between observed and calculated molecular weights for CHST10?

The discrepancy between CHST10's calculated molecular weight (~42 kDa) and its observed weight in Western blot (~72 kDa) is common and can be attributed to several factors :

• Post-translational modifications: Glycosylation, phosphorylation, and sulfation can significantly increase apparent molecular weight

• Protein-protein interactions that resist denaturation

• Structural characteristics affecting protein migration through SDS-PAGE gels

• Incomplete denaturation of the protein during sample preparation

When validating a CHST10 antibody, researchers should consider this molecular weight discrepancy and not automatically dismiss antibodies that detect bands at 72 kDa rather than the calculated 42 kDa. Validation using knockout controls can confirm whether the observed band represents the authentic CHST10 protein despite the apparent molecular weight difference.

What are the optimal conditions for Western blot detection of CHST10?

For optimal Western blot detection of CHST10, researchers should consider the following methodological parameters:

• Sample preparation: Use RIPA or NP-40 buffer with protease inhibitors

• Protein loading: 20-40 μg of total protein per lane is recommended

• Gel percentage: 10-12% SDS-PAGE gels provide optimal resolution

• Transfer conditions: Semi-dry or wet transfer at 100V for 60-90 minutes

• Blocking solution: 5% non-fat dry milk or BSA in TBST

• Primary antibody dilution: 1:500 - 1:2000 dilution is typically effective

• Incubation conditions: Overnight at 4°C for primary antibody

• Detection system: HRP-conjugated secondary antibodies with appropriate chemiluminescent substrate

Researchers should be prepared to detect CHST10 at approximately 72 kDa despite its calculated molecular weight of 42 kDa . Optimization may be required for different sample types, and validation using positive and negative controls is essential to confirm specificity.

What controls are essential when using CHST10 antibodies in immunofluorescence studies?

When conducting immunofluorescence studies with CHST10 antibodies, several controls are critical for ensuring reliable and interpretable results:

• Positive control: Include samples known to express CHST10 (e.g., neural tissue sections)

• Negative control: Ideally, use CHST10 knockout cells or tissues; alternatively, use tissues known not to express CHST10

• Secondary antibody control: Omit primary antibody to assess non-specific binding of the secondary antibody

• Peptide competition control: Pre-incubate the primary antibody with the immunizing peptide

• Multiple antibody validation: When possible, confirm localization patterns with a second CHST10 antibody targeting a different epitope

Research indicates that only 38% of antibodies validated for immunofluorescence by orthogonal approaches were confirmed when tested with knockout controls . This highlights the critical importance of rigorous controls, particularly genetic controls like knockout samples, in immunofluorescence studies.

How should I optimize immunohistochemistry protocols for CHST10 detection?

Optimizing immunohistochemistry (IHC) protocols for CHST10 detection requires careful consideration of several parameters:

• Fixation method: 4% paraformaldehyde is recommended; avoid over-fixation which can mask epitopes

• Antigen retrieval: Test both heat-induced epitope retrieval (citrate buffer, pH 6.0) and enzymatic retrieval methods

• Blocking conditions: Use 5-10% normal serum from the species of the secondary antibody

• Primary antibody concentration: Start with 1:100 - 1:300 dilution and optimize as needed

• Incubation time and temperature: Typically overnight at 4°C or 1-2 hours at room temperature

• Detection system: Choose chromogenic or fluorescent detection based on research needs

• Counterstaining: Use appropriate nuclear counterstains that don't interfere with CHST10 detection

Each new tissue type may require protocol optimization. For human tissues, particularly pathological samples, consider variables such as post-mortem interval and fixation duration that may affect antibody binding. Always include appropriate positive and negative controls in each experiment.

Can CHST10 antibodies validated for mammals be used in non-mammalian models?

Cross-species reactivity of CHST10 antibodies to non-mammalian models requires careful validation. While the anti-CHST10 antibody A30586 has been validated for human, mouse, and rat samples , its reactivity with non-mammalian species like zebrafish has not been definitively established. When considering using mammalian-validated antibodies in non-mammalian models, researchers should:

• Perform sequence homology analysis between the mammalian immunogen and the non-mammalian CHST10 protein

• Conduct preliminary validation experiments with appropriate controls (e.g., CHST10-deficient tissues if available)

• Consider epitope conservation across species

• Validate using multiple applications (WB, IHC, IF) to confirm consistent results

When asked directly about zebrafish cross-reactivity, antibody manufacturers have indicated that while cross-reactivity is possible due to sequence conservation, specific validation in zebrafish has not been performed . Researchers should conduct their own validation experiments before proceeding with large-scale studies in non-mammalian models.

What approaches can be used to confirm cross-species reactivity of CHST10 antibodies?

To confirm cross-species reactivity of CHST10 antibodies, researchers should implement a systematic validation approach:

• Bioinformatic analysis: Compare the antibody's immunogen sequence with the target species' CHST10 sequence to assess homology

• Western blot validation: Test the antibody on tissue lysates from the species of interest, comparing molecular weight and band pattern with known reactive species

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to confirm specific binding

• Genetic knockdown: If possible, use CRISPR or morpholino knockdown in the target species to verify specificity

• Comparative immunohistochemistry: Compare staining patterns across species to evaluate consistency with known CHST10 localization

The approach must be methodical and comparative, with appropriate controls for each technique employed. Successful validation across species enhances the utility of the antibody and can provide valuable insights into evolutionary conservation of CHST10 function.

How can CHST10 antibodies be used in studying protein-protein interactions?

CHST10 antibodies can be powerful tools for investigating protein-protein interactions through several techniques:

• Co-immunoprecipitation (Co-IP): Use CHST10 antibodies to pull down CHST10 and its interacting partners, followed by mass spectrometry or Western blot analysis of co-precipitated proteins

• Proximity ligation assay (PLA): Combine CHST10 antibodies with antibodies against potential interaction partners to visualize protein interactions in situ with single-molecule resolution

• Immunofluorescence co-localization: Use CHST10 antibodies in combination with antibodies against potential interaction partners to assess spatial proximity

• FRET/BRET analysis: Combine CHST10 antibodies with fluorescently labeled secondary antibodies for Förster resonance energy transfer studies

When using immunoprecipitation techniques, it's crucial to select antibodies specifically validated for IP applications, as not all CHST10 antibodies perform equally in this context. For the anti-CHST10 antibody described in the search results, proper validation for IP applications included confirmation that the antibody can successfully immunocapture the target protein from non-denaturing lysates .

What are the best practices for quantifying CHST10 expression levels across different neural cell types?

Quantifying CHST10 expression across neural cell types requires careful methodological considerations:

• Single-cell approaches:

  • Flow cytometry using intracellular staining with CHST10 antibodies

  • Single-cell Western blot for protein-level analysis

  • Immunofluorescence with co-staining for cell-type-specific markers

• Population-level approaches:

  • Cell sorting followed by Western blot analysis

  • Immunohistochemistry with quantitative image analysis

  • ELISA for quantitative measurement in cell lysates

• Quantification methods:

  • Use appropriate internal loading controls for Western blot (β-actin, GAPDH)

  • For imaging, employ unbiased stereological methods and automated analysis

  • Include standard curves with recombinant CHST10 protein for absolute quantification

When comparing expression across cell types, standardization is essential. Consider factors such as cell size differences, protein extraction efficiency, and detection sensitivity. Always include positive and negative controls, and when possible, validate findings using complementary techniques.

How can I determine if my CHST10 antibody has degraded over time?

Monitoring CHST10 antibody quality and detecting potential degradation requires systematic quality control measures:

• Performance comparison:

  • Compare current results with previous experiments using the same antibody lot

  • Test on known positive controls with established signal intensity

  • Look for decreased sensitivity, increased background, or altered staining patterns

• Storage integrity checks:

  • Visually inspect for precipitation, turbidity, or color changes

  • Avoid repeated freeze-thaw cycles that can degrade antibody performance

  • Maintain proper storage conditions (-20°C for long-term; 4°C for frequent use up to one month)

• Quality control experiments:

  • Run a dilution series to assess changes in signal-to-noise ratio

  • Compare with a fresh aliquot or new lot of the same antibody if available

  • Test on standardized positive control samples with expected staining intensity

When degradation is suspected, proper documentation of lot numbers, storage conditions, and experimental observations is crucial for troubleshooting. Consider aliquoting antibodies upon receipt to minimize freeze-thaw cycles and extend shelf life.

How can contradictory results between different CHST10 antibodies be resolved?

Resolving contradictory results between different CHST10 antibodies requires a systematic investigative approach:

• Validation comparison:

  • Review validation methods used for each antibody (genetic vs. orthogonal approaches)

  • Prioritize antibodies validated using knockout controls, which have higher reliability

  • Consider the epitope recognized by each antibody and whether post-translational modifications might affect detection

• Technical validation:

  • Test all antibodies side-by-side under identical conditions

  • Include appropriate positive and negative controls for each antibody

  • Compare results across multiple applications (WB, IF, IHC) if possible

• Literature assessment:

  • Review published literature using the specific antibodies

  • Be aware that approximately 20-35% of published studies may use antibodies that don't properly recognize their targets

  • Contact the antibody manufacturers for additional validation data

When contradictions persist, consider using alternative methods to confirm your findings, such as RNA-level analysis, mass spectrometry, or CRISPR-based genetic approaches. Reporting contradictory results to antibody manufacturers can also help improve product validation.

Table 1: Comparison of different antibody types for CHST10 detection based on validation studies .